Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy
Xinqi Wu(Dana-Farber Brigham Cancer Center), F. Stephen Hodi(Harvard University), Christine J. Pak, Donald P. Lawrence(Massachusetts General Hospital), Ana Lako(Brigham and Women's Hospital), Scott J. Rodig(Brigham and Women's Hospital), Jun Zhou(Brigham and Women's Hospital), Mariano Severgnini(Dana-Farber Cancer Institute), Michael P. Manos(Harvard University), Evisa Gjini(Brigham and Women's Hospital), Mikel Lipschitz(Brigham and Women's Hospital), Xiaoyun Liao(Bristol-Myers Squibb (Germany)), Erin M. Connolly(Dana-Farber Cancer Institute), Courtney Connelly(Brigham and Women's Hospital), Sara Abdelrahman(Dana-Farber Cancer Institute), Jingjing Li(Nantong University), Anita Giobbie‐Hurder(Institute for Tourism), David F. McDermott(Beth Israel Deaconess Medical Center)
Cited by 167
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k